Trial Profile

A Multicenter, Randomized, Double-blind, Active-Controlled Study of the Efficacy and Safety of Flexibly-Dosed BMS-820836 in Patients With Treatment Resistant Major Depression.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Sep 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Liafensine (Primary) ; Duloxetine
Indications Major depressive disorder
Focus Pharmacogenomic; Therapeutic Use

Most Recent Events

15 Dec 2012 Planned end date changed from 1 May 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.
15 Dec 2012 Planned number of patients changed from 1200 to 1400 as reported by European Clinical Trials Database.
14 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com